PVCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PVCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Provectus Biopharmaceuticals's net interest income for the three months ended in Sep. 2024 was $-0.06 Mil. Its net interest income for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.24 Mil.
The historical data trend for Provectus Biopharmaceuticals's Net Interest Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provectus Biopharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Interest Income | Get a 7-Day Free Trial | -1.43 | -1.75 | -0.96 | -0.16 | -0.22 |
Provectus Biopharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Net Interest Income | Get a 7-Day Free Trial | -0.06 | -0.06 | -0.06 | -0.06 | -0.06 |
Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.
Net Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey Allen Morris | 10 percent owner | 1729 TRIANGLE PARK DR., MARYVILLE TN 37801 |
Webster Bailey | director | 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932 |
Heather Raines | officer: Chief Financial Officer | 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932 |
Edward Pershing | director | 2220 SOUTHERLAND AVE, KNOXVILLE TN 37919 |
John Iii Lacy | director | 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932 |
John R Glass | officer: See Remarks | 7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931 |
Bruce Horowitz | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Dominic Rodrigues | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Peter R Culpepper | officer: Interim CEO, CFO, COO | 7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931 |
Eric Phd Wachter | director, officer: Chief Technology Officer | PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Jan Koe | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Smith Alfred E. Iv | director | 191 MAIN STREET, NEW CANAAN CT 06840 |
Kelly M Mcmasters | director | 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
Donald E Adams | 10 percent owner | 370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401 |
Timothy Phd Scott | director, 10 percent owner, officer: President | PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-03-2022
By PurpleRose PurpleRose • 08-17-2022
By Value_Insider Value_Insider • 11-10-2022
By Value_Insider Value_Insider • 12-01-2022
By GuruFocusNews GuruFocusNews • 06-28-2022
By Marketwired • 08-01-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Marketwired • 06-13-2024
By Value_Insider Value_Insider • 12-12-2022
By sperokesalga sperokesalga • 04-20-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.